STX-721-101

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations.

  • Code NKI: M23STX
  • Code firma: STX-721-101
  • Code clinicaltrials.gov: NCT06043817

Principal Investigator

Dr. G. Ruiter

Drugs

STX-721 (small-molecule inhibitor targeting a broad range of EGFR- and HER2-activating mutations in the kinase domain)

Summary

Study STX-721-101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR/HER2 exon 20 insertion (ex20ins) mutations.

Read more on clinicaltrials.gov